Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Altimmune (ALT) over the last 16 years, with Q3 2025 value amounting to $27000.0.

  • Altimmune's Depreciation & Amortization (CF) fell 2702.7% to $27000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $119000.0, marking a year-over-year decrease of 6520.47%. This contributed to the annual value of $238000.0 for FY2024, which is 5240.0% down from last year.
  • Latest data reveals that Altimmune reported Depreciation & Amortization (CF) of $27000.0 as of Q3 2025, which was down 2702.7% from $30000.0 recorded in Q2 2025.
  • In the past 5 years, Altimmune's Depreciation & Amortization (CF) ranged from a high of $285000.0 in Q3 2021 and a low of -$552000.0 during Q3 2023
  • For the 5-year period, Altimmune's Depreciation & Amortization (CF) averaged around -$31894.7, with its median value being $37000.0 (2024).
  • Per our database at Business Quant, Altimmune's Depreciation & Amortization (CF) soared by 29101.62% in 2021 and then plummeted by 105283.02% in 2023.
  • Altimmune's Depreciation & Amortization (CF) (Quarter) stood at $117000.0 in 2021, then crashed by 301.71% to -$236000.0 in 2022, then skyrocketed by 158.05% to $137000.0 in 2023, then tumbled by 75.91% to $33000.0 in 2024, then fell by 18.18% to $27000.0 in 2025.
  • Its last three reported values are $27000.0 in Q3 2025, $30000.0 for Q2 2025, and $29000.0 during Q1 2025.